Search Result

Isoforms Recommended:	DPP-4

Results for "

DPP4,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (2) Autophagy (16) Dipeptidyl Peptidase (74) Ferroptosis (10) GCGR (2) GLP Receptor (3) Glucosidase (3) Glutathione Peroxidase (1) GPR119 (2) Interleukin Related (1) Isotope-Labeled Compounds (6) Neuropeptide Y Receptor (1) NF-κB (1) Phosphatase (1) Potassium Channel (1) Reactive Oxygen Species (1) SARS-CoV (2) Small Interfering RNA (siRNA) (3) TNF Receptor (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (10) Endocrinology (1) Infection (2) Inflammation/Immunology (12) Metabolic Disease (74) Neurological Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS03963

DPP4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DPP4 Human Pre-designed siRNA Set A contains three designed siRNAs for DPP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DPP4 Human Pre-designed siRNA Set A DPP4 Human Pre-designed siRNA Set A

HY-RS03964

Dpp4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dpp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dpp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dpp4 Mouse Pre-designed siRNA Set A Dpp4 Mouse Pre-designed siRNA Set A

HY-RS03965

Dpp4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dpp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dpp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dpp4 Rat Pre-designed siRNA Set A Dpp4 Rat Pre-designed siRNA Set A

HY-103432

DPP4-In	Others	Others
DPP4-In is an active compound.

HY-157390

DPP-4-IN-9	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-9 (compound 6l) is a potent inhibitor of dipeptidyl peptidase *DPP-4* (IC₅₀: 8.22 nM). DPP-4-IN-9 has antihyperglycemic activity .

HY-169110

DPP-4-IN-12	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-12 (compound 46) is a potent *DPP-4* inhibitor with IC₅₀ value of 2 nM. DPP-4-IN-12 can be used in the study of type 2 diabetes .

HY-151383

DPP-4-IN-1	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-1 (compound d1) is a potent *DPP-4* (dipeptidyl peptidase 4) inhibitor, with an IC₅₀of 49 nM. DPP-4-IN-1 is a structurally analogs of Alogliptin (HY-A0023A). DPP-4-IN-1 can be used for diabetes research .

HY-151384

DPP-4-IN-2	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-2 (compound b2) is a potent *DPP-4* (dipeptidyl peptidase 4) inhibitor, with an IC₅₀of 79 nM. DPP-4-IN-2 is a structurally analogs of Alogliptin (HY-A0023A). DPP-4-IN-2 can be used for diabetes research .

HY-162513

DPP-4-IN-10	Dipeptidyl Peptidase	Cardiovascular Disease
DPP-4-IN-10 (compound 1) is a DPP-4 inhibitor. DPP-4-IN-10 is orally active. DPP-4-IN-10 blocks the degradation of GLP-1 and GIP, which may improve glycemic control in type 2 diabetes (T2MD) .

HY-155027

DPP-4-IN-8	Dipeptidyl Peptidase TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
DPP-4-IN-8 (compound 27) is a potent and selective *DPP4* (dipeptidyl peptidase 4) inhibitor, with a K_i of 0.96 μM. DPP-4-IN-8 blocks the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells. DPP-4-IN-8 also dose-dependently suppresses the expression levels of the chemokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) .

HY-159491

DPP-4-IN-11	Dipeptidyl Peptidase Glucosidase Amylases	Metabolic Disease
DPP-4-IN-11 (compound 10) is an orally active *DPP-4* inhibitor (IC₅₀=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC₅₀=3.02 μM) and α-amylase (IC₅₀=3.3 μM) .

HY-146455

DPP-4-IN-3	Dipeptidyl Peptidase Reactive Oxygen Species	Metabolic Disease
DPP-4-IN-3 (Compound 5a) is a potent dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 0.75 nM. DPP-4-IN-3 shows excellent antioxidant and insulinotropic activity .

HY-146468

DPP-4/GPR119 modulator 1	Dipeptidyl Peptidase GPR119 Potassium Channel	Metabolic Disease
DPP-4/GPR119 modulator 1 (Compound 22) is an orally active dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist. DPP-4/GPR119 modulator 1 shows blood glucose-lowering effect and moderate inhibition on hERG channel with an IC₅₀ of 4.9 μM. DPP-4/GPR119 modulator 1 can be used for diabetes research . DPP-4/GPR119 modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146469

DPP-4/GPR119 modulator 2	Dipeptidyl Peptidase GPR119	Metabolic Disease
DPP-4/GPR119 modulator 2 (Compound 20i) is a dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist with an IC₅₀ of 0.22 μM for DPP-IV and an EC₅₀ of 0.95 μM for GPR119. DPP-4/GPR119 modulator 2 can be used for diabetes research . DPP-4/GPR119 modulator 2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14806B

Teneligliptin hydrobromide hydrate 5+ Cited Publications MP-513 hydrobromide hydrate	Dipeptidyl Peptidase	Metabolic Disease
Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based *DPP-4* inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM .

HY-14806A

Teneligliptin hydrobromide 5+ Cited Publications MP-513 hydrobromide	Dipeptidyl Peptidase	Metabolic Disease
Teneligliptin (MP-513) hydrobromide is a potent chemotype prolylthiazolidine-based *DPP-4* inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM.

HY-14806

Teneligliptin 5+ Cited Publications MP-513	Dipeptidyl Peptidase	Metabolic Disease
Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting *DPP-4* inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM .

HY-10284

Linagliptin 5+ Cited Publications BI 1356	Dipeptidyl Peptidase Autophagy Ferroptosis	Metabolic Disease
Linagliptin is a highly potent, selective *DPP-4* inhibitor with IC₅₀ of 1 nM.

HY-147401

Sitagliptin fenilalanil	Dipeptidyl Peptidase	Metabolic Disease
Sitagliptin fenilalanil is a dipeptidyl aminopeptidase 4 (DPP-4) inhibitor .

HY-147401A

Sitagliptin fenilalanil hydrochloride	Dipeptidyl Peptidase	Metabolic Disease
Sitagliptin fenilalanil hydrochloride is a dipeptidyl aminopeptidase 4 (DPP-4) inhibitor .

HY-14806S1

Teneligliptin-d4 MP-513-d₄	Isotope-Labeled Compounds Dipeptidyl Peptidase	Metabolic Disease
Teneligliptin-d₄ is deuterium labeled Teneligliptin. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM[1].

HY-14806R

Teneligliptin (Standard)	Dipeptidyl Peptidase	Metabolic Disease
Teneligliptin (Standard) is the analytical standard of Teneligliptin. This product is intended for research and analytical applications. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting *DPP-4* inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM .

HY-14892

Gemigliptin LC15-0444	Dipeptidyl Peptidase	Metabolic Disease Cancer
Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-161428

ZINC000003015356	Dipeptidyl Peptidase	Metabolic Disease
ZINC000003015356 is a *DPP4* inhibitor .

HY-A0023AS

Alogliptin-13C,d3 SYR-322-¹³C,d₃	Isotope-Labeled Compounds Dipeptidyl Peptidase	Metabolic Disease Cancer
Alogliptin- ¹³C,d₃ is the deuterium labeled Alogliptin. Alogliptin is a potent and selective inhibitor of DPP-4.

HY-14892A

Gemigliptin tartrate LC15-0444 tartrate	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-10284R

Linagliptin (Standard)	Dipeptidyl Peptidase Autophagy Ferroptosis	Metabolic Disease
Linagliptin (Standard) is the analytical standard of Linagliptin. This product is intended for research and analytical applications. Linagliptin is a highly potent, selective *DPP-4* inhibitor with IC₅₀ of 1 nM.

HY-16656

BMS-767778	Dipeptidyl Peptidase	Cancer
BMS-767778 is a selective *DPP4* inhibitor, with a K_i of 0.9 nM .

HY-119266

HTS13517	Dipeptidyl Peptidase	Others
HTS13517 is a *DPP4* inhibitor, with an IC₅₀ of 10.73 μM .

HY-14806S

Teneligliptin-d8 MP-513 d₈	Dipeptidyl Peptidase	Cardiovascular Disease
Teneligliptin-d₈ is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor[1].

HY-112668

Retagliptin phosphate 1 Publications Verification SP2086 phosphate	Dipeptidyl Peptidase	Metabolic Disease
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research .

HY-112668A

Retagliptin 1 Publications Verification SP2086	Dipeptidyl Peptidase	Metabolic Disease
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research .

HY-121029

Bisegliptin KRP-104	Others	Metabolic Disease
Bisegliptin (KRP-104) is a small molecule compound with antidiabetic activity. Bisegliptin is metabolized mainly by converting the cyano group to the carboxylic acid form, and DPP-4 plays a partial role in its metabolism. The carboxylic acid metabolite of bisegliptin can be detected both in vivo and in vitro. In rat experiments, the plasma concentration of the carboxylic acid metabolite of bisegliptin was affected by other DPP inhibitors, showing the complexity of its metabolic process. The amide intermediate of bisegliptin was detected both in vivo and in vitro, and its conversion rate was significantly faster than that of the parent compound when incubated with DPP-4 .

HY-139792

Besigliptin tosylate SHR117887	Others	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-123377

Fotagliptin SAL067 free base	Dipeptidyl Peptidase	Metabolic Disease
Fotagliptin is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC₅₀=2.27 nM). Fotagliptin displays great security in rat and dog. Fotagliptin can be used for Type 2 diabetes mellitus research .

HY-10284S3

Linagliptin-d3-1 BI 1356-d₃-1	Isotope-Labeled Compounds Dipeptidyl Peptidase Autophagy Ferroptosis	Metabolic Disease
Linagliptin-d3-1 (BI 1356-d3-1) is the deuterium labeled Linagliptin (HY-10284). Linagliptin is a highly potent, selective *DPP-4* inhibitor with IC₅₀ of 1 nM .

HY-13749A

Sitagliptin phosphate Maximum Cited Publications 18 Publications Verification MK-0431 phosphate	Dipeptidyl Peptidase Autophagy	Metabolic Disease
Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of *DPP4* with an IC₅₀ of 19 nM in Caco-2 cell extracts .

HY-13749B

Sitagliptin phosphate monohydrate Maximum Cited Publications 18 Publications Verification MK-0431 phosphate monohydrate	Dipeptidyl Peptidase Autophagy	Metabolic Disease
Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent inhibitor of *DPP4* with an IC₅₀ of 19 nM in Caco-2 cell extracts .

HY-123377A

Fotagliptin benzoate SAL067	Dipeptidyl Peptidase	Metabolic Disease
Fotagliptin benzoate is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC₅₀=2.27 nM). Fotagliptin benzoate displays great security in rat and dog. Fotagliptin benzoate can be used for Type 2 diabetes mellitus research .

HY-124958

NDMC101	NF-κB Dipeptidyl Peptidase	Metabolic Disease Inflammation/Immunology
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via *DPP4* inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al .

HY-15408

Trelagliptin SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective *DPP-4* inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-13749

Sitagliptin Maximum Cited Publications 18 Publications Verification MK-0431	Dipeptidyl Peptidase Autophagy	Metabolic Disease
Sitagliptin (MK-0431) is a potent and orally active inhibitor of *DPP4* with an IC₅₀ of 19 nM in Caco-2 cell extracts .

HY-12528

DBPR108	Dipeptidyl Peptidase	Metabolic Disease
DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9.

HY-10285

Saxagliptin 5 Publications Verification BMS-477118	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .

HY-15408A

Trelagliptin succinate SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective *DPP-4* inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-10285A

Saxagliptin hydrate 5 Publications Verification BMS-477118 hydrate	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research .

HY-16448

Saxagliptin hydrochloride 5 Publications Verification BMS-477118 hydrochloride	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research .

HY-14877

Anagliptin 3 Publications Verification SK-0403	Dipeptidyl Peptidase	Cardiovascular Disease Metabolic Disease
Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC₅₀ of 3.8 nM, and less selective at *DPP-8* and DDP-9 with IC₅₀s of 68 nM and 60 nM, respectively .

HY-147257

Cofrogliptin HSK7653	Dipeptidyl Peptidase	Metabolic Disease
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .

HY-14877A

Anagliptin hydrochloride SK-0403 hydrochloride	Dipeptidyl Peptidase	Cardiovascular Disease Metabolic Disease
Anagliptin (SK-0403) hydrochloride is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC₅₀ of 3.8 nM, and less selective at *DPP-8* and DDP-9 with IC₅₀s of 68 nM and 60 nM, respectively .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

793 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 793 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

HY-L012

Metabolism/Protease Compound Library

4,707 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases.

MCE designs a unique collection of 4,707 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P2543

Neuropeptide Y (3-36) (human, rat)	Neuropeptide Y Receptor	Metabolic Disease
Neuropeptide Y (3-36) (human, rat), a neuropeptide Y (NPY) metabolite formed from dipeptidyl peptidase-4 (DPP4), is a selective Y2 receptor agonist. Neuropeptide Y (3-36) (human, rat) is a NPY metabolite formed from dipeptidyl peptidase-4 (DPP4). Neuropeptide Y (3-36) (human, rat) decreases release of norepinephrine via the Y2 receptor .

HY-P1141

GLP-1(9-36)amide	GCGR	Metabolic Disease
GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-P1141A

GLP-1(9-36)amide TFA	GCGR	Metabolic Disease
GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-108795A

Albiglutide fragment TFA GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[4].

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[4].

HY-P6177

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against *DPP4* and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

Cat. No.	Product Name	Target	Research Area

HY-P99466

Begelomab SAND-26	Dipeptidyl Peptidase	Inflammation/Immunology
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against *DPP-4/CD26*. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .

HY-P9805

Anti-MERS-3A1 mAb MERS-3A1; MERS Antibody-3A1	SARS-CoV	Infection
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .

HY-P9806

Anti-MERS-D12 mAb MERS-D12; MERS Antibody-D12	SARS-CoV	Infection
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8134

2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one	Natural Products other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	Dipeptidyl Peptidase
2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one is a natural product found in the leaves and stem bark of M. glabra. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one displays binding affinities with dipeptidyl peptidase-4 (DPP-4) and α-Amylase. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one has potential antidiabetic activities .

Species:	Human (2) Mouse (2) Cynomolgus (3)
Tag:	His (2) Tag Free (2) Fc (3)
Source:	HEK293 (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P72975

	CD26/Dipeptidyl Peptidase 4 Protein, Human (HEK293) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Human	HEK293
	The CD26/dipeptidyl peptidase 4 protein is a cell surface glycoprotein receptor that induces T cell proliferation and NF-kappa-B activation. CD26 also works with FAP to promote pericellular proteolysis, endothelial cell migration, and invasion of the extracellular matrix. CD26/Dipeptidyl Peptidase 4 Protein, Human (HEK293) is the recombinant human-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with tag free. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Human (HEK293) is 738 a.a., with molecular weight of ~95 kDa.

HY-P72976

	CD26/Dipeptidyl Peptidase 4 Protein, Human (HEK293, Fc) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Human	HEK293
	The CD26/dipeptidyl peptidase 4 protein is a cell surface glycoprotein receptor that induces T cell proliferation and NF-kappa-B activation. CD26 also works with FAP to promote pericellular proteolysis, endothelial cell migration, and invasion of the extracellular matrix. CD26/Dipeptidyl Peptidase 4 Protein, Human (HEK293, Fc) is the recombinant human-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Human (HEK293, Fc) is 738 a.a., with molecular weight of 120-130 kDa.

HY-P75428

	CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, His) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Mouse	HEK293
	CD26/dipeptidyl peptidase 4 is a key cell surface receptor for T cell activation. It binds to ADA, CAV1, IGF2R and PTPRC to promote T cell proliferation and NF-kappa-B activation. CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, His) is 732 a.a., with molecular weight of ~85.9 kDa.

HY-P75429

	CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, Fc) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Mouse	HEK293
	CD26/dipeptidyl peptidase 4 is a key cell surface receptor for T cell activation. It binds to ADA, CAV1, IGF2R and PTPRC to promote T cell proliferation and NF-kappa-B activation. CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, Fc) is 732 a.a., with molecular weight of ~122.5 kDa.

HY-P76876

	CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293, His) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Cynomolgus	HEK293
	CD26/Dipeptidyl Peptidase 4 Protein is a serine membrane anchored exopeptidase, belonging to dipeptidyl peptidase (DPP) family. CD26/Dipeptidyl Peptidase 4 Protein is widely expressed in a variety of tissues and many cells. CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293, His) is 733 a.a., with molecular weight of 100-130 KDa.

HY-P76877

	CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293, Fc) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Cynomolgus	HEK293
	CD26/Dipeptidyl Peptidase 4 Protein is a serine membrane anchored exopeptidase, belonging to dipeptidyl peptidase (DPP) family. CD26/Dipeptidyl Peptidase 4 Protein is widely expressed in a variety of tissues and many cells. CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293, Fc) is 733 a.a., with molecular weight of ~113 kDa.

HY-P76875

	CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293) Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4	Cynomolgus	HEK293
	CD26/Dipeptidyl Peptidase 4 Protein is a serine membrane anchored exopeptidase, belonging to dipeptidyl peptidase (DPP) family. CD26/Dipeptidyl Peptidase 4 Protein is widely expressed in a variety of tissues and many cells. CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293) is the recombinant cynomolgus-derived CD26/Dipeptidyl Peptidase 4 protein, expressed by HEK293 , with tag free. The total length of CD26/Dipeptidyl Peptidase 4 Protein, Cynomolgus (HEK293) is 733 a.a., with molecular weight of 92-102 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10284S

Linagliptin-d4
Linagliptin-d₄ is deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. Linagliptin-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13749AS

Sitagliptin-d4 phosphate
Sitagliptin-d₄ (phosphate) is the deuterium labeled Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts[1][2].

HY-A0023AS1

Alogliptin-d3
Alogliptin-d₃ is the deuterium labeled Alogliptin. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes[1][2][3].

HY-14806S1

Teneligliptin-d4
Teneligliptin-d₄ is deuterium labeled Teneligliptin. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM[1].

HY-A0023AS

Alogliptin-13C,d3
Alogliptin- ¹³C,d₃ is the deuterium labeled Alogliptin. Alogliptin is a potent and selective inhibitor of DPP-4.

HY-14806S

Teneligliptin-d8
Teneligliptin-d₈ is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor[1].

HY-10284S3

Linagliptin-d3-1
Linagliptin-d3-1 (BI 1356-d3-1) is the deuterium labeled Linagliptin (HY-10284). Linagliptin is a highly potent, selective *DPP-4* inhibitor with IC₅₀ of 1 nM .

HY-15408S

Trelagliptin-13C,d3
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective *DPP-4* inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-13749S1

Sitagliptin-d4 hydrochloride
Sitagliptin-d₄ (hydrochloride) is the deuterium labeled Sitagliptin[1]. Sitagliptin (MK-0431) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts[2].

HY-10284S1

Linagliptin-13C,d3
Linagliptin- ¹³C,d₃ is the ¹³C- and deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. Linagliptin-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82766

	CD26 Antibody (YA2511) DPP4; ADCP2; CD26; Dipeptidyl peptidase 4; ADABP; Adenosine deaminase complexing protein 2; ADCP-2; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; CD26	WB	Human, Mouse, Rat
	CD26 Antibody (YA2511) is a biotin-conjugated non-conjugated IgG antibody, targeting CD26, with a predicted molecular weight of 88 kDa (observed band size: 110 kDa). CD26 Antibody (YA2511) can be used for WB experiment in human, mouse, rat background.

HY-P81529

	DPP4/CD26 Antibody (YA1274) ADCP2, CD26; DPP4; Dipeptidyl peptidase 4; ADABP; Adenosine deaminase complexing protein 2 (ADCP-2); Dipeptidyl peptidase IV (DPP IV); T-cell activation antigen CD26; TP103	IHC-P	Human
	DPP4/CD26 Antibody (YA1274) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1274), targeting DPP4/CD26. DPP4/CD26 Antibody (YA1274) can be used for IHC-P experiment in human background.